生物谷報(bào)道,，美國(guó)科學(xué)家首次發(fā)現(xiàn)一種可預(yù)測(cè)前列腺癌術(shù)后復(fù)發(fā)的免疫分子,，通過測(cè)定該分子水平，還有助于判斷患者是否需要手術(shù)治療,。該研究結(jié)果發(fā)表在8月15日出版的《癌癥研究》雜志上,。
梅奧診所的Eugene D Kwon醫(yī)生在文章中稱，這種名為B7-H3的分子位于前列腺癌細(xì)胞表面,，參與關(guān)閉機(jī)體免疫應(yīng)答過程,，能夠終止或阻止免疫細(xì)胞對(duì)癌細(xì)胞的攻擊。他們?cè)趯?duì)338名行根治性前列腺切除術(shù)的男性進(jìn)行隨訪研究的過程中發(fā)現(xiàn),，最具攻擊性的腫瘤細(xì)胞該蛋白表達(dá)水平也最高,。另一驚人的發(fā)現(xiàn)是，那些該蛋白水平最高的患者,，其前列腺癌復(fù)發(fā)的危險(xiǎn)性也最高,。所有腫瘤和癌前病變組織均表達(dá)B7-H3，但高水平B7-H3患者癌癥復(fù)發(fā)的可能性是低高水平患者的4倍,，而中等水平B7-H3患者復(fù)發(fā)的風(fēng)險(xiǎn)提高35%,。Kwon醫(yī)生將B7-H3喻為占卜用的“水晶球”，它可預(yù)知術(shù)后腫瘤是否復(fù)發(fā),。此外,，研究人員還認(rèn)為，通過檢測(cè)B7-H3水平,，可確定手術(shù)治療的適宜患者,。研究人員還指出,，通過阻斷B7-H3，可使腫瘤對(duì)機(jī)體免疫應(yīng)答更為敏感,，因而它可能成為新的治療靶點(diǎn),。
但有些專家對(duì)此持懷疑態(tài)度。布萊根婦女醫(yī)院放射腫瘤科主任Dr. Anthony D'Amico 認(rèn)為,，該研究尚不能確定這一標(biāo)記物與已知其它標(biāo)記物相比,，是否能夠提供新的信息。美國(guó)癌癥學(xué)會(huì)副會(huì)長(zhǎng)Dr. Len Lichtenfeld指出,，目前前列腺癌標(biāo)記物研究目標(biāo)是發(fā)現(xiàn)那些能夠篩查出前列腺癌是否屬于侵襲性類型的標(biāo)記物,，而這一新的標(biāo)記物在這一方法或許有所幫助。他還認(rèn)為將會(huì)發(fā)現(xiàn)更多的生物標(biāo)記物,，最終可通過檢查癌癥組織和這些標(biāo)記物,，能夠找到可提供更多有關(guān)預(yù)后和治療準(zhǔn)確信息的特征。
Figure 1. A to C, B7-H3 expression is observed in prostate cancer tumors and increases with Gleason score: 19.2% of cases showed weak (A) intensity typically in Gleason pattern 3 + 3 tumors, 61.0% of cases showed moderate (B) tumor B7-H3 intensity typically in Gleason 3 + 4 tumors, and 19.8% of cases showed marked (C) tumor B7-H3 intensity in large neoplastic glands typically of Gleason 4 + 4 tumors.
原文出處：
Cancer Research August 15 2007, Volume 67, Issue 16
B7-H3 Ligand Expression by Prostate Cancer: A Novel Marker of Prognosis and Potential Target for Therapy
Timothy J. Roth, Yuri Sheinin, Christine M. Lohse, Susan M. Kuntz, Xavier Frigola, Brant A. Inman, Amy E. Krambeck, Maureen E. Mckenney, R. Jeffrey Karnes, Michael L. Blute, John C. Cheville, Thomas J. Sebo, and Eugene D. Kwon
Cancer Res 2007 67: 7893-7900. Published Online First August 8, 2007. doi: 10.1158/0008-5472.CAN-07-1068 [Abstract] [Full Text] [PDF] Supplementary Data
相關(guān)基因：
CD276
Official Symbol CD276 and Name: CD276 molecule [Homo sapiens]
Other Aliases: B7-H3, B7H3
Other Designations: B7 homolog 3; CD276 antigen
Chromosome: 15; Location: 15q23-q24
Annotation: Chromosome 15, NC_000015.8 (71763675..71793912)
MIM: 605715
GeneID: 80381
作者簡(jiǎn)介：
Eugene D. Kwon, M.D.
Summary
Research in the Kwon Lab focuses on methods to evoke a potent immune response to treat relatively advanced forms of malignancy. Specific areas of research pertain to the preclinical and clinical use of novel vaccines and antibodies to activate antitumoral T cells; the use of hormone manipulations to boost or rebuild host immunity; the treatment of patients with immunotherapy in order to induce clinical tumor regression. A special emphasis is placed on developing highly state-of-the-art immunotherapies to be tested in clinical phase I or II trials to treat patients with prostate, kidney or bladder cancer. Research in the Kwon Lab is supported by a DOD NI Award (PC 991568), DOD IDEA Award (PC020574), NCI/NIH R01 (CA82185), a CaPCure Award and a new DOD-sponsored multi-center Phase II Trial Award (DAMD 17-02-1-0245 & DAMD 17-02-1-0245S1) entitled "A phase II immunotherapeutic trial; combined androgen ablative therapy and CTLA-4 blockade as a treatment for advanced prostate cancer".
Recent publications
See a listing of my publications
Education
Post Doctoral Fellowship – National Research Service Award
Laboratory of Kidney & Electrolyte Metabolism, National Heart, Lung and Blood Institute, National Institutes of Health
Chief Resident – Urology
University of Iowa Hospitals and Clinics
Residency – Urology
University of Iowa Hospitals and Clinics
Research Fellowship – Urology and Internal Medicine
University of Iowa Hospitals and Clinics
Clinical Fellowship – Clinical Oncology Fellow
American Cancer Society, University of Iowa Hospitals and Clinics
Residency – General Surgery
University of Iowa Hospitals and Clinics
M.D.
Rush Medical College
B.A. – Chemistry
Grinnell College
